Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
CD52 Biologics Sequence Review Report 2026: CAMPATH-1 antigen Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CD52 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CD6 Biologics Sequence Review Report 2026: T-cell differentiation antigen CD6 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CD6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL4 Biologics Sequence Review Report 2026: C-C motif chemokine 4 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL8 Biologics Sequence Review Report 2026: C-C motif chemokine 8 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL8 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CD180 Biologics Sequence Review Report 2026: CD180 antigen Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CD180 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL7 Biologics Sequence Review Report 2026: C-C motif chemokine 7 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL7 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL5 Biologics Sequence Review Report 2026: C-C motif chemokine 5 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL22 Biologics Sequence Review Report 2026: C-C motif chemokine 22 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL22 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL3 Biologics Sequence Review Report 2026: C-C motif chemokine 3 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL26 Biologics Sequence Review Report 2026: C-C motif chemokine 26 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL26 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL19 Biologics Sequence Review Report 2026: C-C motif chemokine 19 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
8 min read
CCL20 Biologics Sequence Review Report 2026: C-C motif chemokine 20 Similarity and Patent-Risk Signals
7 August 2026
A Biology Modality MCP review of CCL20 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.